ProBioGen Executes Master Service Agreement with NextPoint Therapeutics

ProBioGen announced on Aug. 17, 2022 that it has closed a Master Service Agreement with NextPoint Therapeutics to initiate development and good manufacturing practice manufacturing of its lead antibody candidate.

ProBioGen’s CHO RIGHT cell line development, including their DirectedLuck transposase and platform processes, enable the development to provide a high-expressing stable cell line and a robust manufacturing process. According to the press release, ProBioGen’s proprietary cell culture medium makes is designed to improve protein titers and cell growth behavior.

"We are proud NextPoint has selected us for this fast-track [chemistry, manufacturing, and controls] development and manufacturing of its unique antibody that targets a novel immune checkpoint axis offering promise for hard to treat cancers,” said Gabriele Schneider, Chief Business Officer, ProBioGen, in the press release. “We are thrilled to support them with our expertise and technology to move this candidate towards the clinic.”